HDAC9 and Miyoshi myopathy: If sufficient evidence for SOX7 can be obtained supporting a tumor suppressive role through functional studies, re-expression of silenced SOX7 through the administration of epi-drugs such as HDAC inhibitors [52] can be considered as a targeted therapy option for MM and allied neoplasms.